Elanco Animal Health (ELAN) Tops Q4 EPS by 3c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Elanco Animal Health Reports Fourth Quarter and Full Year 2020 Results
February 24, 2021 6:30 AM ESTFourth quarter 2020 revenue was $1,139.7 million, growth of 45 percent, comprised of $743.4 million from the legacy Elanco portfolio and $396.3 million from the legacy Bayer portfolio. Full year 2020 revenue was $3,273.3 million, growth of 7 percent, comprised of $2,681.4 million from the legacy Elanco portfolio and $591.9 million from the legacy Bayer portfolio. Fourth quarter 2020 earnings per share (EPS) was $(0.66) (reported), or $0.12 (adjusted). Full year 2020 EPS was $(1.27) (reported), or $0.47 (adjusted). Raising financial guidance for the full year 2021 with revenue of $4.55 to $4.63 billion, and diluted EPS of $(0.30) to $(0.20) on a reported basis, or $0.90 to $1.00 on an adjusted basis.... More
